ISSN: 2261-7434
Victor Manuel Vargas Hernandez
Menopausal hormone therapy (THM) is fraught with controversy, and post-reproductive health is quite challenging. It has gone through many years of ups and downs. We recognize that comorbidity is more common after menopause, and we must need preventive measures to avoid it. When THM was used uniformly, the risk-benefit ratio became unfavorable, and its usage plummeted; nevertheless, more recent studies also introduced the idea of a “window of opportunity,” in which THM has no negative side effects and actually prevents comorbidities associated with menopause.